BALTIMORE – Drugmakers that want to develop standalone medical devices to be used in combination with their drugs should evaluate the devices’ capabilities and requirements while engaging health authorities early, according to a panel of experts who spoke at the AFDO/RAPS Combination Products Summit on Tuesday.